ASCO GU 2021: Adjuvant Nivolumab for Advanced Urothelial Carcinoma Shows Benefits
CheckMate 274 results implicate nivolumab monotherapy as new standard of care
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.